Response to Yilmaz et al
Anticancer Drugs
.
2024 Jun 1;35(5):481-482.
doi: 10.1097/CAD.0000000000001585.
Epub 2024 Apr 3.
Authors
Santiago Cabezas-Camarero
1
,
María Cruz Iglesias-Moreno
2
,
Elena Cerezo Druet
3
,
Miguel J Sotelo
4
5
6
,
Salomé Merino-Menéndez
7
,
María Nieves Cabrera-Martín
8
,
José Carlos Plaza-Hernández
9
,
Pedro Pérez-Segura
1
Affiliations
1
Medical Oncology Department, Instituto de Investigación Sanitaria San Carlos (IdISSC).
2
Department of Otolaryngology-Head and Neck Surgery, Instituto de Investigación Sanitaria San Carlos (IdISSC).
3
Radiation Oncology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain.
4
Medical Oncology Department, Aliada Cancer Center, Lima, Perú.
5
Medical Oncology Department, Clínica San Felipe, Lima, Perú.
6
Medical Oncology Department, Hospital María Auxiliadora, Lima, Perú.
7
Radiology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain.
8
Nuclear Medicine Department, Hospital Clínico Universitario San Carlos, Hospital Clínico Universitario San Carlos, Madrid, Spain.
9
Pathology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain.
PMID:
38567818
DOI:
10.1097/CAD.0000000000001585
No abstract available